Billionaires Holding MGNX

BILLIONAIRE ALLOCATION SHARES OWNED (M) % CO AVG. COST RETURN

FUNDAMENTALS

  • N/A
    PE

  • 0.0
    Yield

  • 34.2M
    Shares Outstanding

  • 779.3M
    Market Cap

News & Insights

ABOUT

MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its propr...

Apple And Berkshire Hathaway: When Two Worlds Collide

NEWS

Icahn: Best Bet On Commodities

READ MORE